CNS Pharmacology: Antidepressants and Lithium

Introduction/Overview

Central nervous system (CNS) pharmacology encompasses a diverse array of agents designed to modulate neuronal signaling pathways implicated in mood, anxiety, and affective disorders. Antidepressants, established over several decades, have evolved from broad-spectrum tricyclic agents to highly selective serotonin reuptake inhibitors (SSRIs) and beyond. Lithium, a monovalent cation, remains unique in its mood-stabilizing properties, particularly within bipolar affective disorder. The clinical relevance of these agents is underscored by the high prevalence of depressive and bipolar disorders worldwide, coupled with the need for personalized treatment strategies that balance efficacy with tolerability. Understanding the pharmacologic foundations of antidepressants and lithium informs evidence-based prescribing, risk mitigation, and therapeutic monitoring.

Learning objectives:

• Identify the major classes of antidepressants and describe their chemical classifications.
• Explain the pharmacodynamic mechanisms underlying antidepressant and lithium action.
• Summarize key pharmacokinetic parameters and dosing considerations for both drug categories.
• Recognize therapeutic indications, off‑label uses, and critical adverse effect profiles.
• Apply knowledge of drug interactions and special population considerations to optimize patient care.

Classification

Antidepressants

Antidepressants are traditionally grouped according to their primary pharmacologic targets and chemical structures:

• Selective serotonin reuptake inhibitors (SSRIs) – e.g., fluoxetine, sertraline, escitalopram.
• Serotonin–norepinephrine reuptake inhibitors (SNRIs) – e.g., venlafaxine, duloxetine.
• Tricyclic antidepressants (TCAs) – e.g., amitriptyline, imipramine.
• Monoamine oxidase inhibitors (MAOIs) – e.g., phenelzine, selegiline.
• Atypical antidepressants – e.g., bupropion, mirtazapine, trazodone, vortioxetine.

Within each class, chemical subclasses exist (e.g., newer SSRIs such as escitalopram are chiral derivatives). The classification facilitates anticipation of pharmacokinetic behavior, receptor occupancy, and adverse effect spectra.

Lithium

Lithium carbonate represents a singular therapeutic class characterized by its inorganic cationic nature. Although it lacks a traditional “chemical classification” in the sense of organic drug families, it is grouped with mood stabilizers such as valproate and carbamazepine. Lithium’s therapeutic profile is defined by its narrow therapeutic index and reliance on renal excretion.

Mechanism of Action

Antidepressants

Mechanistic pathways are class‑specific yet often converge on modulation of serotonergic, noradrenergic, dopaminergic, or cholinergic systems.

SSRIs

SSRIs increase extracellular serotonin by competitively inhibiting the serotonin transporter (SERT). The elevated synaptic serotonin enhances postsynaptic receptor activation, particularly 5‑HT1A and 5‑HT2 subtypes, which ultimately leads to antidepressant effects. Chronic SSRI administration is associated with receptor desensitization and downstream neuroplastic changes.

SNRIs

SNRIs block both SERT and the norepinephrine transporter (NET), thereby increasing synaptic serotonin and norepinephrine. The dual increase is hypothesized to produce synergistic antidepressant activity, especially in patients with both mood and pain components.

TCAs

TCAs inhibit reuptake of norepinephrine and serotonin through SERT and NET inhibition. Additionally, they exhibit antagonism at histamine H1, muscarinic M1, and alpha‑1 adrenergic receptors, contributing to their side effect profile. The blockade of reuptake increases synaptic concentrations of monoamines, which modulates neuronal firing patterns in cortical and limbic circuits.

MAOIs

MAOIs irreversibly inhibit monoamine oxidase enzymes (MAO‑A and MAO‑B), preventing the oxidative deamination of serotonin, norepinephrine, dopamine, and other trace amines. The resultant rise in monoamine availability amplifies neurotransmission. The irreversible nature of inhibition explains the dietary restrictions required to avoid hypertensive crises.

Atypical Antidepressants

Atypical agents possess heterogeneous mechanisms. Bupropion primarily inhibits dopamine and norepinephrine reuptake (DAT and NET) and has minimal serotonergic activity. Mirtazapine antagonizes central α2‑adrenergic autoreceptors, enhancing norepinephrine and serotonin release, while also blocking 5‑HT2 and H1 receptors. Trazodone acts as a serotonin antagonist and reuptake inhibitor (SARI), and vortioxetine modulates multiple serotonin receptors (5‑HT3, 5‑HT1A, 5‑HT7) in addition to SERT inhibition.

Lithium

Lithium exerts its mood‑stabilizing effects through multiple intracellular pathways. It inhibits glycogen synthase kinase‑3β (GSK‑3β), thus modulating gene transcription and neuronal signaling. Lithium also antagonizes inositol monophosphatase (IMPase), disrupting phosphatidylinositol signaling and reducing neuronal excitability. Additionally, lithium may influence voltage‑gated sodium channels and adenylyl cyclase, thereby attenuating hyperactive neuronal firing in mania. The convergence of these mechanisms is thought to underlie lithium’s efficacy in preventing mood episodes.

Pharmacokinetics

Antidepressants

Absorption is generally rapid following oral administration, with peak plasma concentrations (Cmax) reached within 1–4 hours. Bioavailability varies: SSRIs (e.g., sertraline) exhibit ∼50 % oral bioavailability, whereas TCAs (e.g., amitriptyline) have higher bioavailability but significant first‑pass metabolism. Metabolism predominantly occurs in the liver via cytochrome P450 enzymes (CYP2D6, CYP2C19, CYP3A4), leading to active or inactive metabolites. Excretion routes include renal (∼30–40 %) and fecal pathways. Half‑lives (t½) differ markedly: fluoxetine t½ ≈ 4 days (active metabolite nor‑fluoxetine extends duration), while venlafaxine t½ ≈ 5 hours. Dosing frequency is typically once daily; extended‑release formulations allow for reduced dosing intervals.

Pharmacokinetic Considerations

• Polymorphisms in CYP2D6 significantly influence SSRI metabolism, leading to variable plasma levels.
• Drug–drug interactions via P‑gp or CYP inhibition/induction can alter drug exposure.
• Age, hepatic function, and comorbidities influence clearance rates.

Lithium

Lithium is absorbed efficiently from the gastrointestinal tract, with oral bioavailability approaching 90 %. Distribution follows a two‑compartment model; the apparent volume of distribution (Vd) is approximately 0.6 L kg‑1. Renal excretion is the primary elimination pathway, with the kidneys filtering and reabsorbing lithium via proximal tubules. The elimination half‑life is about 18–24 hours in adults, but may be prolonged in chronic therapeutic use due to the accumulation of lithium in renal tissues. The narrow therapeutic index (trough serum concentration 0.6–1.2 mmol L‑1 for efficacy; toxicity > 1.5 mmol L‑1) necessitates routine serum level monitoring. Dosage adjustments are required in the presence of renal impairment, diuretic use, or sodium‑restricted diets.

Therapeutic Uses/Clinical Applications

Antidepressants

Approved indications include major depressive disorder (MDD), generalized anxiety disorder (GAD), obsessive‑compulsive disorder (OCD), post‑traumatic stress disorder (PTSD), and panic disorder. Off‑label uses are common and include the treatment of chronic pain (duloxetine), smoking cessation (bupropion), and adjunctive therapy for bipolar depression (certain SSRIs or SNRIs). SSRIs and SNRIs are first‑line agents for many anxiety disorders; TCAs and MAOIs are reserved for refractory cases or when specific side‑effect profiles align with patient characteristics.

Lithium

Lithium is considered the gold standard for treating acute mania and for long‑term prophylaxis of bipolar affective disorder. It also reduces the risk of suicide in high‑risk populations. Off‑label applications include adjunctive therapy in treatment‑resistant depression and as a neuroprotective agent in neurodegenerative conditions; however, evidence for these uses is less robust. Lithium’s efficacy is most pronounced in bipolar I disorder, with limited benefit in bipolar II or schizoaffective disorders.

Adverse Effects

Antidepressants

Side effect profiles are class‑specific but often overlap.

SSRIs

• Sexual dysfunction (decreased libido, delayed orgasm).
• Gastrointestinal upset (nausea, diarrhea).
• Sleep disturbances (insomnia or somnolence).
• Weight changes (variable).
• Serotonin syndrome risk when combined with other serotonergic agents.
• Black‑box warning for increased suicidal ideation in adolescents and young adults.

SNRIs

• Hypertension, particularly early in therapy.
• Serotonin syndrome with concomitant serotonergic drugs.
• Similar sexual and gastrointestinal side effects as SSRIs.

TCAs

• Anticholinergic effects: dry mouth, blurred vision, constipation, urinary retention.
• Cardiac conduction abnormalities: QRS prolongation, arrhythmias.
• Hypotension due to alpha‑1 blockade.
• Sedation, weight gain.

MAOIs

• Orthostatic hypotension.
• Hypertensive crisis with tyramine‑rich foods.
• Serotonin syndrome.
• Neuroleptic malignant syndrome with antipsychotic co‑administration.

Atypical Antidepressants

• Bupropion: risk of seizures at high doses.
• Mirtazapine: sedation, weight gain, increased appetite.
• Trazodone: orthostatic hypotension, priapism (rare).
• Vortioxetine: mild headache, nausea.

Lithium

• Tremor (fine, postural), often dose‑dependent.
• Polyuria, polydipsia due to nephrogenic diabetes insipidus.
• Weight gain, mild sedation.
• Nephrotoxicity: chronic interstitial nephritis, reduced glomerular filtration.
• Thyroid dysfunction: hypothyroidism or hyperthyroidism.
• Neurotoxicity: at concentrations > 1.5 mmol L‑1; manifestations include ataxia, seizures, coma.
• Black‑box warning for the risk of accidental overdose and associated toxicity.

Drug Interactions

Antidepressants

• SSRIs and SNRIs combined with MAOIs can precipitate serotonin syndrome; a washout period of ≥ 14 days is recommended.
• TCAs are potentiated by antihistamines, anticholinergics, or sedatives, increasing sedation and anticholinergic burden.
• MAOIs interact with sympathomimetic drugs (e.g., phenylephrine) and tyramine‑containing foods, leading to hypertensive crises.
• All antidepressants inhibit CYP2D6 to varying degrees, potentially raising serum levels of co‑administered drugs metabolized by this enzyme.
• Serotonin‑ergic agents (e.g., triptans, linezolid) increase risk of serotonin syndrome when combined with SSRIs/SNRIs.

Lithium

• Diuretics (thiazide, loop) and NSAIDs reduce renal clearance of lithium, raising serum concentrations.
• ACE inhibitors, ARBs, and angiotensin‑converting enzyme inhibitors can potentiate lithium toxicity.
• High‑salt diets or dehydration can increase lithium reabsorption, while high‑sodium intake can reduce lithium levels.
• Concurrent use of carbamazepine or valproate may alter lithium clearance.
• Beta‑blockers and calcium channel blockers can modestly increase serum lithium due to reduced renal perfusion.

Special Considerations

Pregnancy and Lactation

SSRIs have a low teratogenic risk but may be associated with persistent pulmonary hypertension of the newborn when used late in pregnancy. SNRIs and MAOIs carry higher risks of fetal complications. TCAs and atypical agents have limited data; caution is advised. Lithium exposure during pregnancy is linked to a small increased risk of Ebstein anomaly; however, untreated bipolar disorder poses its own risks. Lactation is generally discouraged during lithium therapy due to the potential for neonatal toxicity; most antidepressants are excreted into breast milk at low levels but require individualized assessment.

Pediatric and Geriatric Populations

In children and adolescents, SSRIs are indicated for depression and anxiety, but the risk of suicidality necessitates close monitoring. Off‑label use of bupropion for ADHD is common. In older adults, polypharmacy increases the likelihood of drug interactions; anticholinergic burden from TCAs can precipitate cognitive decline. Lithium dosing must account for age‑related decreases in renal function, and serum monitoring is particularly important in the elderly.

Renal and Hepatic Impairment

For antidepressants, hepatic impairment may prolong drug half‑life and increase plasma concentrations, especially for CYP2D6 substrates. Renal impairment generally has a lesser impact but can affect the excretion of certain metabolites. Lithium clearance is dramatically reduced in renal impairment, necessitating dose reductions and more frequent serum level checks. Hepatic dysfunction can also lead to accumulation of lithium metabolites, raising toxicity risk.

Summary/Key Points

Antidepressants

• Multiple classes target monoamine systems; each has distinct receptor profiles and side effect spectra.
• SSRIs and SNRIs are first‑line for most depressive and anxiety disorders; TCAs and MAOIs are reserved for treatment‑resistant cases.
• Pharmacokinetic variability driven by CYP polymorphisms requires individualized dosing and monitoring.
• Drug–drug interactions, particularly involving serotonergic agents and CYP inhibitors, must be anticipated.
• Pregnancy, lactation, and special populations necessitate careful risk–benefit assessment.

Lithium

• Effective for acute mania and long‑term prophylaxis of bipolar disorder; narrow therapeutic index mandates serum monitoring.
• Renal excretion underlies dosing adjustments in renal impairment and interactions with diuretics, NSAIDs, and ACE inhibitors.
• Adverse effect profile includes tremor, polyuria, thyroid dysfunction, and potential nephrotoxicity; neurotoxicity requires prompt recognition.
• Pregnancy and lactation pose additional risks; counseling and monitoring are essential.
• Therapeutic drug monitoring and patient education are critical components of safe lithium therapy.

These pharmacologic insights provide a foundation for clinical decision‑making, enabling practitioners to tailor therapies to individual patient profiles while mitigating adverse outcomes.

References

1. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.